Through a $1m Australian Commonwealth Government grant for rapid resourcing of our genome engineering and model import services, we offer subsidised access to specific mouse strains for COVID-related research, either produced domestically or sourced internationally.
The models currently/soon to be available are:
Gt(ROSA)26Sortm1(mAce2-hAce2)WEHI
Human ace2 cDNA expressed under the regulation of the mouse ace2 promoter, this is a knock-in into the Rosa26 safe harbour locus.
Gt(ROSA)26Sortm2.1(hFoxj1-hAce2)WEHI
Human ace2 cDNA expressed under the regulation of the human foxj1 promoter (in reverse orientation), this is a knock-in into the Rosa26 safe harbour locus.
Gt(ROSA)26Sortm2.2(hFoxj1-hAce2)WEHI (in pipeline)
Human ace2 cDNA expressed under the regulation of the human foxj1 promoter (in forward orientation), this is a knock-in into the Rosa26 safe harbour locus.
C56BL/6J-Tg(mAce2-hAce2)MGMP
Human ace2 cDNA expressed under the regulation of the mouse ace2 promoter, this is transgenic animal model. The integration of the Human ace2 cDNA is random. We have several animals available with a different copy number count (low copy number, medium copy number and high copy number)
C56BL/6J-Tg(mAce2-hACE2)SAGE (in pipeline)
Human ace2 cDNA expressed under the regulation of the mouse ace2 promoter, this is transgenic animal model. The integration of the Human ACE2 cDNA is random.
B6.Cg-Tg(K18-ACE2)2Prlmn/JArc
K18-hACE2 transgenic mice express human ACE2, the receptor used by the severe acute respiratory syndrome coronavirus (SARS-CoV) to gain entry to cells. The human keratin 18 (KRT18) promoter directs expression to epithelia, including airway epithelial cells where infections typically begin. This model of lethal infection with SARS-CoV mimics the human SARS disease. Recent research indicates this line may be useful in studying antiviral therapies for the 2019 novel coronavirus (SARS-CoV-2) pathogenesis and the disease outbreak COVID-19. More info.
Contact us to know more about the Phenomics Australia COVID-19 models available.
Phenomics Australia In vivo Genome Engineering & Disease Modelling:
Phenomics Australia provides a national centre of expertise and service provision to deploy CRISPR for increased speed, efficiency, and decreased cost for the production of animal strains carrying targeted mutations while maintaining the expertise for traditional transgenic technologies. To meet the high demand for this platform, Phenomics Australia offers genome editing services through four nodes across Australia, operating at Monash, ANU, WEHI, and SAHMRI.
With an established track record and reputation for excellence, our Genome Engineering team uses techniques such as CRISPR-mediated mutagenesis, classical gene targeting, and transgenesis to create optimal tools for your research delivering a comprehensive service in genome modification. Phenomics Australia continues to develop and expand mutagenesis capabilities through in-house research and development, information exchange between service nodes, other CRISPR practitioners, and thorough literature review, thereby establishing a national community of practice for genome engineering technologies and applications. With our collective experience and expertise in a wide variety of projects, Phenomics Australia can assist in the production of genetically modified animal models using mice, rats, and rabbits. By providing a leading capability to make genetic associations with disease, Phenomics Australia makes the cost of investigating pathways associated with disease affordable.
